S100A4
S100A4proteinAlarmin driving macrophage-mediated plaque inflammation and structural instability.
Pathway placement
Cascade stepPlaque inflammation
Confidencemedium
RationaleS100 family member promotes monocyte/macrophage activity and matrix remodeling in plaque.
Also acts inCap degradation / rupture
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000196154
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I20
C — confounder / Type-II59
A — assay feasibility68
E — evidence strength22
T1DI (composite)5
Specificity differential (R−C)-38.7
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(1)
- Serum S100A4 levels as a novel biomarker for detection of acute myocardial infarction.European review for medical and pharmacological sciences · 2015 · PMID 26166646